Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Research & Development (2023 - 2025)

Monte Rosa Therapeutics' Research & Development history spans 3 years, with the latest figure at $42.0 million for Q4 2025.

  • For Q4 2025, Research & Development rose 8.01% year-over-year to $42.0 million; the TTM value through Dec 2025 reached $141.5 million, up 16.4%, while the annual FY2025 figure was $141.5 million, 16.4% up from the prior year.
  • Research & Development reached $42.0 million in Q4 2025 per GLUE's latest filing, up from $36.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $42.0 million in Q4 2025 to a low of $26.8 million in Q1 2023.
  • Average Research & Development over 3 years is $31.2 million, with a median of $28.7 million recorded in 2023.
  • The largest YoY upside for Research & Development was 43.23% in 2024 against a maximum downside of 3.51% in 2024.
  • A 3-year view of Research & Development shows it stood at $27.1 million in 2023, then skyrocketed by 43.23% to $38.9 million in 2024, then increased by 8.01% to $42.0 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Research & Development are $42.0 million (Q4 2025), $36.7 million (Q3 2025), and $30.7 million (Q2 2025).